Come up with a name for your new list and we'll add to it:
Seragon Pharmaceuticals was acquired by
Genentech on July 02, 2014.
Seragon is focused on developing new treatments for estrogen-driven cancers based on its Selective Estrogen Receptor Degrader (SERD) platform. Seragon Pharmaceuticals' orally active selective estrogen…